Target Name: NME2
NCBI ID: G4831
Other Name(s): epididymis secretory sperm binding protein Li 155an | c-myc transcription factor | non-metastatic cells 2, protein (NM23) expressed in | NDK B | NM23B | NDPKB | histidine protein kinase NDKB | Nucleoside diphosphate kinase B (isoform a) | NDKB | Non-metastatic cells 2, protein (NM23B) expressed in | NDPK-B | PUF | nm23-H2 | c-myc purine-binding transcription factor PUF | NME/NM23 nucleoside diphosphate kinase 2 | Nucleoside diphosphate kinase B | HEL-S-155an | NDKB_HUMAN | NME2 variant 1 | non-metastatic cells 2, protein (NM23B) expressed in | C-myc purine-binding transcription factor PUF | nucleotide diphosphate kinase B | NM23-H2 | NDP kinase B | Histidine protein kinase NDKB | NME/NM23 nucleoside diphosphate kinase 2, transcript variant 1

NME2 as a Potential Drug Target and Biomarker for EpiDermis Secretory Sperm Binding Protein Li155an

Abstract:

EpiDermis secretory sperm binding protein (Li155an) is a protein that plays a crucial role in the development and maintenance of skin tissue. The NME2 gene, which encodes this protein, has been identified as a potential drug target and biomarker for various skin diseases. This article will discuss the potential mechanisms by which NME2 could be targeted as a drug and the diagnostic implications of Li155an as a biomarker.

Introduction:

EpiDermis secretory sperm binding protein (Li155an) is a transmembrane protein that is expressed in various tissues, including skin, gut, and reproductive organs. It is known to play a vital role in the development, migration, and differentiation of skin tissue, and has has been implicated in several skin diseases, including eczema, psoriasis, and dermatitis.

Recent studies have identified NME2 as a potential drug target for Li155an. The NME2 is a non-coding RNA molecule that is highly expressed in various tissues and has been implicated in several biological processes, including cell signaling, DNA replication, and gene regulation. The gene has also been associated with several diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

Drug Targeting NME2:

The NME2 gene has been identified as a potential drug target for Li155an due to its involvement in several cellular processes that are relevant to skin development and maintenance. One of the main mechanisms by which NME2 could be targeted is through its role in cell signaling. NME2 has been shown to play a role in several signaling pathways that are involved in skin development and maintenance, including the TGF-β pathway and the Wnt pathway.

Additionally, NME2 has been shown to be involved in the regulation of cellular processes that are critical for skin development, such as cell adhesion, migration, and differentiation. Its expression has been shown to be regulated by several factors, including cytokines, growth factors, and chemokines. Therefore, targeting NME2 could provide new insights into the mechanisms underlying skin development and maintenance.

Biomarker Potential:

Li155an has also been identified as a potential biomarker for several skin diseases. Its expression has been shown to be elevated in several skin diseases, including eczema, psoriasis, and dermatitis. Additionally, studies have shown that Li155an has been associated with several other proteins that are involved in skin disease, including TGF-β, collagen, and keratin.

In conclusion, NME2 is a protein that has been identified as a potential drug target for Li155an due to its involvement in several cellular processes that are relevant to skin development and maintenance. Further research is needed to understand the mechanisms by which NME2 could be targeted and its potential as a biomarker for skin diseases.

Protein Name: NME/NM23 Nucleoside Diphosphate Kinase 2

Functions: Major role in the synthesis of nucleoside triphosphates other than ATP. The ATP gamma phosphate is transferred to the NDP beta phosphate via a ping-pong mechanism, using a phosphorylated active-site intermediate (By similarity). Negatively regulates Rho activity by interacting with AKAP13/LBC (PubMed:15249197). Acts as a transcriptional activator of the MYC gene; binds DNA non-specifically (PubMed:8392752, PubMed:19435876). Binds to both single-stranded guanine- and cytosine-rich strands within the nuclease hypersensitive element (NHE) III(1) region of the MYC gene promoter. Does not bind to duplex NHE III(1) (PubMed:19435876). Has G-quadruplex (G4) DNA-binding activity, which is independent of its nucleotide-binding and kinase activity. Binds both folded and unfolded G4 with similar low nanomolar affinities. Stabilizes folded G4s regardless of whether they are prefolded or not (PubMed:25679041). Exhibits histidine protein kinase activity (PubMed:20946858)

More Common Targets

NME2P1 | NME3 | NME4 | NME5 | NME6 | NME7 | NME8 | NME9 | NMI | NMNAT1 | NMNAT2 | NMNAT3 | NMRAL1 | NMRAL2P | NMRK1 | NMRK2 | NMS | NMT1 | NMT2 | NMTRQ-TTG10-1 | NMTRQ-TTG12-1 | NMTRV-TAC1-1 | NMU | NMUR1 | NMUR2 | NNAT | NNMT | NNT | NNT-AS1 | NOA1 | NOB1 | NOBOX | NOC2L | NOC2LP2 | NOC3L | NOC4L | NOCT | NOD1 | NOD2 | NODAL | NOG | NOL10 | NOL11 | NOL12 | NOL3 | NOL4 | NOL4L | NOL4L-DT | NOL6 | NOL7 | NOL8 | NOL9 | NOLC1 | NOM1 | NOMO1 | NOMO2 | NOMO3 | Non-protein coding RNA 185 | NONO | NOP10 | NOP14 | NOP14-AS1 | NOP16 | NOP2 | NOP53 | NOP56 | Nop56p-associated pre-rRNA complex | NOP58 | NOP9 | NOPCHAP1 | NORAD | NOS1 | NOS1AP | NOS2 | NOS2P1 | NOS2P2 | NOS2P3 | NOS3 | NOSIP | NOSTRIN | Notch ligands | Notch receptor | Notch Transcriptional Activation Complex | NOTCH1 | NOTCH2 | NOTCH2NLA | NOTCH2NLC | NOTCH3 | NOTCH4 | NOTO | NOTUM | NOVA1 | NOVA1-DT | NOVA2 | NOX1 | NOX3 | NOX4 | NOX5 | NOXA1 | NOXO1